Jonathan J. Darrow is a faculty member at Harvard Medical School and is a member of the Program on Regulation, Therapeutics, and Law (PORTAL) at Brigham & Women’s Hospital. He holds degrees in biological sciences / genetics, law, and business from Cornell, Duke, and Boston College, respectively, as well as a research doctorate in pharmaceutical policy and intellectual property theory from Harvard, where he also completed the LL.M. program. He has been qualified as a patent attorney since 2002. After admission to the California bar, Dr. Darrow worked on pharmaceutical litigation matters at Wiley Rein & Fielding in Washington, DC, taught on the business law faculties of three universities, served as a senior law clerk for a federal appellate judge, and explored the relationship between innovation policy and global health in service to the World Trade Organization, the World Health Organization, and the World Intellectual Property Organization. He is a co-author of three textbooks, including Cyberlaw: Management & Entrepreneurship (2015) and The Legal and Ethical Environment of Business (2014). His scholarship on health policy and intellectual property has appeared in the British Medical Journal, the New England Journal of Medicine (2,3); the Journal of Law, Medicine & Ethics; the Stanford Technology Law Review; the Yale Journal of Health Policy Law & Ethics, and Health Affairs, among many others, and he has testified before a committee of the Massachusetts legislature on an emerging issue of law and technology.


Recent Posts by Jonathan Darrow

The Future Of Precision Medicine: Great Promise, Significant Challenges

Central to the PMI is the All of Us Research Program, which aims to enroll 1 million or more volunteers throughout the United States. If successful, it would be one of the largest longitudinal cohorts ever developed in this country.

New Drug And Device Approval: What Is Sufficient Evidence?

Editor's note: In addition to Jonathan Darrow, this post is also coauthored by Aaron Kesselheim.  The federal Food, Drug, and Cosmetic Act gives the Food and Drug Administration (FDA) the authority to evaluate all prescription drugs and high-risk medical devices before they can be marketed...